Noble In $1.2 Billion Ultra-Deepwater Rig Contract

Noble Corp said Hyundai Heavy Industries will build two ultra-deepwater drillships for the world's second largest offshore drilling contractor by fleet size for about $1.21 billion.

Wednesday's news, along with recent orders from Dryships, Pride International, and Norway's Seadrill, bolsters the belief the Gulf of Mexico deepwater market will continue to rebound despite reversals following the oil spill in April last year.

Under the contract, the rigs - designed to work in water-depths of up to 12,000 feet - will likely be delivered in the second and fourth quarters of 2013.
The $605-million rigs are likely to commence operations by 90-120 days after delivery, Switzerland-based Noble said. The deal includes a fixed-price option for up to two more drillships, to be declared by May 2011 for 2014, it added.

"The fundamentals of the global ultra-deepwater market will continue to be strong in the decade ahead," Noble Chief Executive David Williams said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.